Actively Recruiting

Phase Not Applicable
Age: 33Weeks - 48Weeks
All Genders
ID05568264

Early Detection and Therapeutic Improvement of Motor Delay in High Risk Infants: A Randomized, Controlled Trial

Led by Shirley Ryan AbilityLab · Updated on 2025-05-21

222

Participants Needed

3

Research Sites

30 weeks

Total Duration

On this page

Sponsors

S

Shirley Ryan AbilityLab

Lead Sponsor

A

Ann & Robert H Lurie Children's Hospital of Chicago

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are conducting a randomized controlled trial to study motor delays in infants admitted to the Neonatal Intensive Care Unit (NICU). The study aims to evaluate an early physical therapy intervention intended to improve motor function and reduce motor delays by 12 months corrected age. It also seeks to assess early effects of the intervention before 12 months and examine whether caregiver-focused support improves caregiver well-being. Infants will be randomly assigned to either an intervention group receiving up to two therapist visits per week in addition to standard care or a standard care group. The intervention begins in the NICU and continues until 12 months corrected age. Caregivers receive resources and guidance to engage in activities with their infants throughout the day. All participants may also access other therapies or medical services as recommended. Participants will undergo assessments at scheduled intervals up to 12 months corrected age, with optional follow-ups at 18 and 24 months. These include motor function tests, movement quality monitoring using wearable sensors, and caregiver well-being surveys. Medical records will be reviewed to track standard care services. Caregivers may be invited to focus groups or interviews about the study experience. The main measurement is the Bayley-4 motor score at 12 months corrected age.

CONDITIONS

Brief Title

Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

Who Can Participate

Age: 33Weeks - 48Weeks
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Infant admitted to NICU and qualifies for high-risk early intervention due to birth weight less than 1500 grams or central nervous system disorders including brain injury or developmental abnormalities
  • Infant with bronchopulmonary dysplasia requiring respiratory support at 36 weeks postmenstrual age if born before 32 weeks gestation
  • Medically stable infant able to start intervention between 34 and 48 weeks postmenstrual age
  • Caregivers able to speak English
Not Eligible

You will not qualify if you...

  • Open wounds or skin conditions preventing sensor placement
  • Immune deficiencies needing protective isolation
  • Limb reduction defects
  • Primarily followed in another clinic for certain conditions (e.g., meningomyelocele, trisomy 21)
  • Bleeding disorders or ongoing anticoagulation
  • Receiving palliative or hospice care for life-limiting conditions
  • Known visual impairment at enrollment
  • Child under Department of Children and Family Services custody
  • Non-English speaking caregivers
  • Any other condition preventing study participation as determined by the principal investigator
  • Previously enrolled in competing randomized trials with developmental outcome variables

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - From as early as possible in the NICU until 12 months corrected age

Participants in the intervention group receive up to two therapist visits per week in addition to standard of care physical therapy. Caregivers work with their infant on activities provided by the therapist throughout the day. Participants in the standard of care group continue with routine care. All participants complete assessments and surveys at defined time points to monitor development and caregiver engagement.

Up to 2 therapist visits per week plus scheduled assessments at enrollment, monthly up to 3 months corrected age, and at 3, 6, 9, and 12 months corrected age

Follow-up

Duration - Optional visits at 18 and 24 months corrected age

Optional assessments and surveys continue at 18 and 24 months corrected age to further evaluate motor and cognitive development and caregiver well-being.

Optional visits at 18 and 24 months corrected age

Trial Site Locations

Total: 3 locations

1

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

2

Northwestern Medicine Prentice Children's Hospital

Chicago, Illinois, United States, 60611

Actively Recruiting

3

Children's Hospital at the University of Illinois

Chicago, Illinois, United States, 60612

Actively Recruiting

Loading map...

Research Team

E

Elizabeth Hoffman, DPT

S

Sara Prokup, DPT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase 2b Study Evaluating OHB-607 Compared to Standard Neo...

Bronchopulmonary Dysplasia

Actively Recruiting

66 locations

A Phase IIb Dose Escalation Study of Levetiracetam for the T...

Neonatal Seizure

Actively Recruiting

5 locations

A Randomized Control Trial of a Responsive Parenting Interve...

Premature Birth

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Protocol for a randomized controlled trial to evaluate a year-long (NICU-to-home) evidence-based, high dose physical therapy intervention in infants at risk of neuromotor delay.

Weiyang Deng, Sofia Anastasopoulos, Raye-Ann deRegnier...

https://pubmed.ncbi.nlm.nih.gov/37725613